[Corrigendum] Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population

Following the publication of the above paper, it was drawn to the authors’ attention by an interested reader that, regarding the flow cytometric experiments in Fig. 1C on p. 3, the ‘T24/CML’ and ‘J82/TMZ’ plots were apparently matching, suggesting that this figure had been assembled incorrectly. In addition, concerning the colony formation assay data in Fig. 1B, the ‘T24/0 μM’ and ‘J82/20 μM’, and ‘J82/0 μM’ and T24/20 μM’ pairings of images were apparently the same. Furthermore, upon performing an independent analysis of the data in this paper in the Editorial Office, it came to light that, regarding the scratch‑wound assay images shown in Fig. 1D, the J82/0 h/T24 panel contained a small overlapping section with the T24/0 h/TMZ panel, such that these data panels were derived from the same original source, where different experimental conditions were described. In addition, it also came to light that the data panel shown for the J82/CTL experiment in Fig. 3B was apparently matching with a data panel that was published in a paper in Cancer Gene Therapy in 2015 featuring the corresponding author (Yongbaek Kim) in common (entitled “Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines”). Upon consulting their original data, the authors have realized that mistakes were made regarding the assembly of Figs. 1 and 3. The authors have repeated the colony formation assay experiments (Fig. 1B), the flow cytometric assay experiments (Fig. 1C) and the scratch‑wound assay experiments (Fig. 1D), and provided the correct data panel for the J82/CTL experiment in Fig. 3B, and the revised versions of Figs. 1 and 3, featuring the revised data in Fig. 1B‑D and in Fig. 3B, are shown on the next two pages. Although the results obtained in the repeated experiments are very similar to those of the original experiments, showing that the replacement of these data has not altered the overall conclusions reported in this study, the descriptions of the data in the Results for these figures should now be revised to the following (changes are highlighted in bold): For Fig. 1B and C: “Quantification of the cell fractions revealed apoptotic cells (Q2 + Q4) in 0.03±0.05% of the control group and 0.02±0.03% of the TMZ‑treated T24 cells, and 0.05±0.05% of the control group and 0.04±0.04% of the TMZ‑treated J82 cells (Fig. 1C).” In addition, concerning the description of the results for Fig. 3B, the relevant text should now read as follows: “Similarly, TMZ treatment decreased the SP fraction of J82 cells from 0.8 to 0.3%.” The authors are grateful to the Editor of Oncology Letters for allowing them the opportunity to publish this Corrigendum, and all the authors agree with its publication. They also thank the reader of the article for drawing these matters to their attention, and apologize to the readership for any inconvenience caused. [Oncology Letters 22: 845, 2021; DOI: 10.3892/ol.2021.13106]